Pages that link to "Q40929262"
Jump to navigation
Jump to search
The following pages link to Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line (Q40929262):
Displaying 50 items.
- Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients (Q21144211) (← links)
- Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors (Q24616065) (← links)
- Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies (Q24645225) (← links)
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine (Q24652443) (← links)
- Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene (Q24794747) (← links)
- Systemic therapies for pancreatic cancer--the role of pharmacogenetics (Q27021716) (← links)
- Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy (Q28484288) (← links)
- Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy (Q28547017) (← links)
- Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells (Q29937967) (← links)
- A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors (Q33382443) (← links)
- A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research (Q33394505) (← links)
- A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors (Q33402598) (← links)
- RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. (Q33793009) (← links)
- Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. (Q34360074) (← links)
- Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein (Q34555685) (← links)
- RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum (Q34625373) (← links)
- A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance (Q35000541) (← links)
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma (Q35483623) (← links)
- Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1 (Q35610203) (← links)
- Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles (Q35909171) (← links)
- An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone (Q35945507) (← links)
- False cell lines: The problem and a solution (Q36296670) (← links)
- The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression. (Q36553206) (← links)
- Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? (Q36610851) (← links)
- In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. (Q36612195) (← links)
- miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. (Q37040632) (← links)
- 14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression (Q37109577) (← links)
- Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma (Q37553543) (← links)
- The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer (Q37641572) (← links)
- Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer. (Q37660290) (← links)
- DNA polymerase eta and chemotherapeutic agents (Q37807048) (← links)
- Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy (Q39327140) (← links)
- Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells. (Q39379544) (← links)
- Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. (Q39496138) (← links)
- Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2 (Q39511381) (← links)
- Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line (Q39642451) (← links)
- Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues (Q40374312) (← links)
- Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. (Q40460534) (← links)
- Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors (Q41616227) (← links)
- Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. (Q41992351) (← links)
- Survival prediction of stage I lung adenocarcinomas by expression of 10 genes (Q42585784) (← links)
- Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides (Q43688395) (← links)
- Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas (Q44023706) (← links)
- Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. (Q44561304) (← links)
- Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. (Q55447773) (← links)
- Antibody-assisted target identification reveals afatinib, an EGFR covalent inhibitor, down-regulating ribonucleotide reductase. (Q55509033) (← links)
- Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism (Q57175017) (← links)
- RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine (Q58759056) (← links)
- Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy (Q85322930) (← links)
- Chemoresistance in Pancreatic Cancer (Q90080192) (← links)